Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. This evidence concerns the gene ERBB2 and head and neck squamous cell carcinoma.